MetaNovas secures Series A+ and A++ financing, Agentic AI drives industrialization of molecular R&D and empowers innovation in consumer health materials

Recently, MetaNovas, a technology company enabling the global first commercial application of AI-designed novel molecular materials, announced the completion of its Series A+ and Series A++ financing rounds. This investment round was jointly backed by industry leaders including the top 5 Chinese domestic brand Kangaroo Mommy, OEM partner AYAN Biotech, as well as financial institutions focused on AI and deep technology such as GRC SinoGreen Fund and Hillhouse Funds. Previously, MetaNovas' Series A round was co-led by Hillhouse Ventures and Pagoda Top Capital, with follow-on investment from RYC. Even earlier, MetaNovas secured a nearly USD 10 million angel round from Redhill Capital and Sinopharm Capital. 

This intensive multi-round capital infusion not only underscores the capital market's strong recognition of MetaNovas' technological implementation capabilities and commercial value in the field of AI-driven molecular R&D, but also signifies that Agentic AI technology has officially become the core underlying logic in molecular discovery. It is propelling AI for Science from a research paradigm towards industrial reality in the development of consumer health materials, including medical devices and cosmetic ingredients.

MetaNovas is deeply engaged in the AI for Science sector, focusing on the core industry pain point in molecular R&D: "significant emphasis on generation, but insufficient attention to implementation." Leveraging its full-chain systematic capabilities,  MetaNovas has achieved the critical leap from "AI-designed molecules" to "AI-implemented molecules," establishing itself as a rare benchmark enterprise capable of truly bringing AI-designed novel molecules and materials to commercial markets such as healthcare.

Currently, the AI for Science sector is experiencing a surge in momentum, with numerous players pursuing breakthroughs in individual technological areas such as molecular generation and structural optimization. However, the field of materials and molecular R&D imposes stringent requirements regarding safety, regulatory compliance, and long-term validation. As the number of molecular candidates grows exponentially, the core bottleneck in the industry has long shifted from "whether molecules can be generated" to "how to screen for high-quality molecules that are commercializable, implementable, and valuable." For a novel material in the consumer health sector to progress from design to market entry, it must navigate multiple hurdles including interdisciplinary reasoning, process adaptation, regulatory filing, and stability validation. This constitutes a complex systematic engineering challenge, and it is precisely where MetaNovas' core competitiveness lies.

Unlike most companies in the industry, which focus on optimizing individual models, MetaNovas has transcended the single-point technology mindset by developing MetAmigo, an Agentic AI proprietary system tailored for the molecular R&D sector. MetAmigo is not merely a predictive model; it functions as an "intelligent R&D organization" in the form of software, effectively addressing the industry's core pain point—the lack of "judgment capability."

MetAmigo is capable of conducting systematic reasoning across multiple disciplines—including biology, chemistry, physics, and materials science—breaking down the technical barriers of individual fields. It performs multi-objective decision-making in highly uncertain R&D environments, balancing core requirements for healthcare material development such as molecular performance, process adaptability, and regulatory compliance. At the same time, it integrates process standards and regulatory constraints upfront throughout the entire R&D workflow, reducing the cost of commercial implementation from the outset. Through a positive data feedback loop of "Agent proposal—expert review—wet lab validation—strategy update," MetAmigo enables deep human-machine reinforcement learning and continuous evolution, allowing the R&D process to iteratively improve over time.

Leveraging this core technological system, MetaNovas has delivered tangible results in commercial implementation, establishing itself as one of the first companies globally to achieve the commercial application of AI-designed novel molecular materials. Currently, novel molecules designed by MetaNovas' AI have been successfully integrated into the product lines of leading cosmetics and medical device brands in both China and the United States. Having secured global compliance filings for novel materials, MetaNovas has achieved full-chain connectivity from laboratory R&D to consumer market application. This demonstrates that AI for Science is no longer merely a technical concept confined to the laboratory, but has evolved into a hardcore productive force capable of generating genuine commercial value in healthcare-related fields such as medical devices and consumer health. This is the core reason why consumer health industry capital has chosen to make significant investments in MetaNovas.

For leading financial institutions focused on AI and deep technology, such as Hillhouse Funds and GRC SinoGreen Fund, the Agentic AI technology infrastructure built by MetaNovas represents a rare long-term investment opportunity. MetaNovas' proprietary multi-agent decision-making architecture, its self-developed closed-loop interdisciplinary system, precise uncertainty modeling capabilities, and scalable technology framework are not merely a single product model—they constitute an "operating system" capable of supporting the upgrading of the entire molecular R&D industry. This infrastructure-oriented technological approach aligns with the long-term development logic of the deep tech sector and elevates competition in molecular R&D from a battle of individual models to a contest of full-chain systemic capabilities.

MetaNovas' technological implementation and industry breakthroughs are inseparable from its founding team, which possesses deep industrial experience and technical expertise. Co-founder and CTO Dr. Yu Lun holds a Ph.D. from MIT in Nuclear Science and Engineering, with a focus on AI. As a rare top-tier technical talent who completed his direct Ph.D. program at MIT in just four years, Dr. Yu Lun previously served as Lead Data Scientist at UnitedHealth Group prior to founding MetaNovas, where he led the development of large-scale machine learning and experimental platforms, accumulating extensive experience in deploying complex AI systems. Under his leadership, MetaNovas has successfully industrialized core technologies including large-scale molecular language models and physics-driven integrated prediction model systems. These have been deeply integrated with MetaNovas' proprietary wet lab systems, laying a solid foundation for the industrial implementation of its technologies.

Dr. Lun Yu, Co-founder and CTO of MetaNovas Biotech

In core industries heavily reliant on molecular R&D—such as healthcare, advanced manufacturing, and consumer upgrading—the field of molecular discovery is undergoing a critical paradigm shift. Over the past three decades, industry development has centered around "improving R&D success rates." However, in the coming decade, "mastering the core judgment in molecular R&D" will become the focal point of industry competition. The value of a single high-quality molecule will ultimately evolve with market demand, but a full-chain operating system capable of determining "how molecules are designed, screened, and implemented" represents the core asset that will sustain continuous industry advancement.

The Agentic AI operating system built by MetaNovas elevates AI from a mere "assistive tool" in molecular R&D to a "core decision-maker." It liberates human R&D personnel from high-frequency, low-value screening tasks, allowing them to focus on higher-level decision-making and creation. This model also provides a replicable template for the commercial implementation of AI for Science in areas such as consumer health material development.

The completion of this financing round will serve as a significant opportunity for MetaNovas to deepen its technological R&D and expand its industry presence. Moving forward, MetaNovas will continue to focus on the development and advancement of its Agentic AI materials system, with a particular emphasis on core healthcare material R&D areas such as medical devices and biopharmaceuticals. MetaNovas aims to drive the transformation of AI for Science from theory to reality across more molecular R&D-related industries, reshaping the molecular discovery landscape through AI technology and injecting new momentum into material innovation and advancement within the healthcare sector.

According to investors, molecular R&D serves as the foundational core for industries including healthcare, advanced manufacturing, and consumer upgrading—sectors characterized by high growth potential and significant ceilings. MetaNovas stands out as one of the few companies in the industry that has achieved commercial implementation of AI-designed novel molecular materials. Its proprietary Agentic AI technology system has established substantial industry barriers, enabling full-chain integration from technological development to commercial application. Investors particularly recognize MetaNovas' approach of deeply integrating AI technology with the industrial requirements of molecular R&D. The technological infrastructure it has built not only supports its own product implementation but also has the potential to drive advancement across the entire molecular R&D industry. Looking ahead, investors will continue to provide resource support to help MetaNovas achieve ongoing breakthroughs in AI-driven molecular discovery and further deepen its industry presence in core areas such as consumer health. They express confidence in MetaNovas becoming a global leader in the industrialization of molecular R&D.